Evaluation Sub-Committee - Applications Considered
- 1196.2 - rTMS for the treatment of depression
- 1342.5 - Oncotype DX
- 1435.1 - Processing and cryopreservation (freezing) of ovarian tissue (complete or partial ovary removal)
- 1510.1 - Emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with Haemophilia A
- 1515 - Endoscopic placement and removal of an intra-gastric balloon for the management of overweight and obesity, in a high-risk patient group who have failed first line treatments
- 1519.1 - Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive lymphoma
- 1525 - LDR Brachytherapy for intermediate and high-risk prostate cancer
- 1562 - Streamlining of MSAC assessment of positron emission tomography project
- 1579 - Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with moderate to severe Haemophilia A (congenital Factor VIII deficiency) without Factor VIII inhibitors
- 1589 - Prognostic value of the number of copies of the survival of motor neurone 2 gene for the severity of spinal muscular atrophy to determine eligibility for nusinersen in asymptomatic patients